Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT02685826Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2016
- Primary completion
- Dec 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 8
01
Overview
Phase 2, open-label trial of durvalumab in multiple myeloma (MM) (3 cohorts), sponsored by Celgene Corporation. Primary endpoint: Participants With Dose-Limiting Toxicities. Started Apr 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02685826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685826.